Latest Royalties News

Vital Metals has reported exceptional surface assay results from its Nechalacho Rare Earths and Niobium Project in Canada, revealing ultra-high-grade mineralisation beyond its flagship Tardiff deposit. These findings underpin an aggressive resource expansion strategy ahead of a 2027 Pre-Feasibility Study.

Minerals 260 has locked in a $220 million strategic funding deal with Franco-Nevada, boosting development and de-risking the Bullabulling Gold Project in Western Australia. This marks Franco-Nevada’s largest Australian investment to date.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Ramelius Resources reports a statutory loss for H1 FY26 driven by Spartan acquisition expenses, yet underlying EBITDA rises on higher gold prices. Integration of Dalgaranga and progress on Rebecca-Roe signal growth ahead.

Perseus Mining reported a 5% revenue increase to US$608.5 million for the half-year ended December 2025, despite an 8% drop in net profit and a 26% decline in gold production. The company declared a steady interim dividend and outlined ongoing operational challenges and corporate restructuring.

88 Energy has released a significant update to its South Prudhoe prospective resource estimates, revealing over 500 million barrels of oil and NGLs gross across multiple reservoirs on Alaska’s North Slope. The company is advancing well planning and farm-out talks targeting a 2027 drilling campaign.

IGO Limited reports a marked improvement in its half-year results, narrowing losses and boosting cash flow amid operational challenges and strategic asset sales.

PLS Group has acquired Calix’s stake in their joint lithium processing venture, gaining full ownership and operational control while securing a royalty-free licence for Calix’s calciner technology.

Alcoa of Australia has partnered with the federal government to overhaul the environmental approvals process for its Western Australian mining operations, committing $55 million to conservation efforts and securing operational certainty through 2045.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

Albright Metals has agreed to sell a significant portion of its Bryah Basin tenements to Catalyst Metals for $1 million cash plus $800,000 in shares, enabling a sharper focus on its Canadian gold and antimony projects.

Starpharma reports a $1.37 million profit for H1 FY26, driven by a major upfront payment from Genentech and progress in its radiopharmaceutical pipeline. The biotech also expands its consumer health footprint amid growing partnerships.